Tivic Health Systems Inc (TIVC) - Net Assets
Based on the latest financial reports, Tivic Health Systems Inc (TIVC) has net assets worth $16.80 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.61 Million) and total liabilities ($14.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Tivic Health Systems Inc operating cash flow efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.80 Million |
| % of Total Assets | 53.14% |
| Annual Growth Rate | 38.57% |
| 5-Year Change | 26.56% |
| 10-Year Change | N/A |
| Growth Volatility | 255.29 |
Tivic Health Systems Inc - Net Assets Trend (2019–2025)
This chart illustrates how Tivic Health Systems Inc's net assets have evolved over time, based on quarterly financial data. Also explore TIVC current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Tivic Health Systems Inc (2019–2025)
The table below shows the annual net assets of Tivic Health Systems Inc from 2019 to 2025. For live valuation and market cap data, see TIVC market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.80 Million | +562.60% |
| 2024-12-31 | $2.54 Million | -29.19% |
| 2023-12-31 | $3.58 Million | -1.38% |
| 2022-12-31 | $3.63 Million | -72.65% |
| 2021-12-31 | $13.27 Million | +1227.61% |
| 2020-12-31 | $-1.18 Million | -149.64% |
| 2019-12-31 | $2.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tivic Health Systems Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4518400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Components | $69.39 Million | 413.12% |
| Total Equity | $16.80 Million | 100.00% |
Tivic Health Systems Inc Competitors by Market Cap
The table below lists competitors of Tivic Health Systems Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dios Exploration Inc.
V:DOS
|
$2.53 Million |
|
AdvancedAdvT Ltd
LSE:ADVT
|
$2.53 Million |
|
Great Western Mining Corp Plc
IR:8GW
|
$2.53 Million |
|
Global Health Ltd
AU:GLH
|
$2.54 Million |
|
Atomic Minerals Corp
V:ATOM
|
$2.53 Million |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
$2.52 Million |
|
TELES Informationstechnologien AG
XETRA:TLIK
|
$2.52 Million |
|
SThree plc
LSE:STEM
|
$2.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tivic Health Systems Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,535,000 to 16,797,000, a change of 14,262,000 (562.6%).
- Net loss of 8,878,000 reduced equity.
- New share issuances of 18,546,000 increased equity.
- Other factors increased equity by 4,594,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.88 Million | -52.85% |
| Share Issuances | $18.55 Million | +110.41% |
| Other Changes | $4.59 Million | +27.35% |
| Total Change | $- | 562.60% |
Book Value vs Market Value Analysis
This analysis compares Tivic Health Systems Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $103.09 | $0.88 | x |
| 2020-12-31 | $-51.10 | $0.88 | x |
| 2021-12-31 | $379.93 | $0.88 | x |
| 2022-12-31 | $37.53 | $0.88 | x |
| 2023-12-31 | $76.74 | $0.88 | x |
| 2024-12-31 | $0.01 | $0.88 | x |
| 2025-12-31 | $58.45 | $0.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tivic Health Systems Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2324.08%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.88x
- Recent ROE (-52.85%) is above the historical average (-146.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -174.95% | -987.62% | 0.14x | 1.28x | $-4.39 Million |
| 2020 | 0.00% | -423.14% | 0.56x | 0.00x | $-3.52 Million |
| 2021 | -64.00% | -728.47% | 0.08x | 1.13x | $-9.82 Million |
| 2022 | -278.13% | -548.70% | 0.31x | 1.66x | $-10.46 Million |
| 2023 | -230.28% | -701.02% | 0.23x | 1.44x | $-8.60 Million |
| 2024 | -223.08% | -725.00% | 0.28x | 1.11x | $-5.91 Million |
| 2025 | -52.85% | -2324.08% | 0.01x | 1.88x | $-10.56 Million |
Industry Comparison
This section compares Tivic Health Systems Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,884,446,440
- Average return on equity (ROE) among peers: -48.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tivic Health Systems Inc (TIVC) | $16.80 Million | -174.95% | 0.88x | $2.53 Million |
| Abbott Laboratories (ABT) | $26.81 Billion | 22.24% | 1.51x | $148.99 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $17.10 Million |
| Aethlon Medical Inc (AEMD) | $5.12 Million | -261.31% | 0.44x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $10.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $9.82 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.99 Million |
| Artivion Inc (AORT) | $24.90 Million | 15.66% | 0.41x | $1.10 Billion |
| Apyx Medical Inc (APYX) | $6.39 Million | 7.83% | 0.24x | $153.68 Million |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offe… Read more